No Data
No Data
希瑪眼科:年度報告 2023
The associated corporation of Hima Ophthalmology (03309.HK) was granted an additional 400,000 shares of common stock by Lam Shun Chao, worth approximately HK$800,000
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, 2021, Lam Shun-chao increased his OTC share holdings of $Hima Ophthalmology (03309.HK) $ with an average price of HK$2.0 per share by 400,000 shares, worth approximately HK$800,000. After the increase in holdings, Lin Shunchao's latest shareholding number of shares in the associated corporation was 900,000 shares, with a good position ratio of 10.00%. Photo Source: Stock Exchange Shareholding Disclosure
Lam Shun Chao sold 2.3 million common shares of the associated corporation of Hima Ophthalmology (03309.HK) worth approximately HK$14.352 million off the market
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, Lam Shun-chao sold 2.3 million common shares of the allied corporation Health Hope Pharma Limited worth about HK$14.352 million on March 11 at an average price of HK$6.24 per share. After the sale, Lin Shunchao's latest shareholding in the associated corporation was 4.7 million shares, and the good position ratio dropped from 70.00% to 47.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange
The associated corporation of Hima Ophthalmology (03309.HK) obtained an additional shareholding of 6.993 million shares of common stock from Lam Shun Chao, worth about HK$6.993 million
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, Lam Shun-chao increased his OTC share holdings of $Hima Ophthalmology (03309.HK) $ on March 1 by an average price of HK$1.0 per share, to a value of about HK$6.993 million. After the increase in holdings, Lin Shunchao's latest shareholding number of shares in the associated corporation was 7 million shares, with a good position ratio of 70.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, the majority shareholder (holding 5% of the shares
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Hima Ophthalmology (3309.HK): Mainland dental performance is impressive, and the Greater Bay Area business is worth looking forward to
Event: On March 26, 2024, Hima Ophthalmology released its 2023 report. The company achieved revenue of HK$1,924 million (+11.09%) and gross profit of HK$619 million (+38.25%), EDITDA
No Data